Trillium Therapeutics Inc. is an immuno-oncology company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on TRIL’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Trillium could be a solid choice for investors.
Current Quarter Estimates for TRIL
In the past 30 days, one estimate has gone higher for Trillium while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 20 cents a share 30 days ago, to a loss of 9 cents today, a move of 55%.
Current Year Estimates for TRIL
Meanwhile, Trillium’s current year figures are also looking quite promising, with two estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 47 cents per share 30 days ago to a loss of 32 cents per share today, an increase of 31.9%.
Bottom Line
The stock has also started to move higher lately, adding 28.7% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Image: Bigstock
Increased Earnings Estimates Seen for Trillium (TRIL): Can It Move Higher?
Trillium Therapeutics Inc. is an immuno-oncology company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on TRIL’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Trillium could be a solid choice for investors.
Current Quarter Estimates for TRIL
In the past 30 days, one estimate has gone higher for Trillium while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 20 cents a share 30 days ago, to a loss of 9 cents today, a move of 55%.
Current Year Estimates for TRIL
Meanwhile, Trillium’s current year figures are also looking quite promising, with two estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 47 cents per share 30 days ago to a loss of 32 cents per share today, an increase of 31.9%.
Trillium Therapeutics Inc. Price and Consensus
Trillium Therapeutics Inc. price-consensus-chart | Trillium Therapeutics Inc. Quote
Bottom Line
The stock has also started to move higher lately, adding 28.7% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>